# Aptose Biosciences Inc. (APTO) Source: https://www.quantisnow.com/company/APTO Generated: 2026-11-08T03:47:20.020Z - Ticker: APTO - Exchange: NASDAQ - Sector: Health Care - Industry: Biotechnology: Biological Products (No Diagnostic Substances) - Website: aptose.com ## About Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1a/b clinical trial for the treatment of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed/refractory acute myeloid leukemia. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada. ## Latest APTO news and filings - 2025-12-06 13:00 UTC [Aptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations](https://www.quantisnow.com/insight/aptoses-tuspetinib-triple-drug-therapy-featured-at-the-2025-ash-6305849) - 2025-05-05 11:00 UTC [Conference Announcement] [Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial](https://www.quantisnow.com/insight/aptose-provides-clinical-update-for-the-tuspetinib-based-triple-drug-frontline-6016949) - 2025-04-23 21:00 UTC [SEC Form 8-K] [Aptose Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aptose-biosciences-inc-filed-sec-form-8-k-regulation-fd-disclosure-5998720) - 2025-04-23 21:00 UTC [Aptose Announces Auditor Not Standing for Re-Appointment](https://www.quantisnow.com/insight/aptose-announces-auditor-not-standing-for-re-appointment-5998711) - 2025-04-23 11:30 UTC [Conference Announcement] [Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference](https://www.quantisnow.com/insight/aptose-to-present-at-the-2025-bloom-burton-co-healthcare-5997268) - 2025-04-23 10:04 UTC [SEC Form PRER14A filed by Aptose Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-prer14a-filed-by-aptose-biosciences-inc-5997092) - 2025-04-21 21:28 UTC [SEC Form 8-K] [SEC Form 8-K filed by Aptose Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-aptose-biosciences-inc-5995159) - 2025-04-17 21:08 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Aptose Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-aptose-biosciences-inc-5992819) - 2025-04-03 20:27 UTC [SEC Form 8-K] [SEC Form 8-K filed by Aptose Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-aptose-biosciences-inc-5975777) - 2025-04-01 12:30 UTC [SEC Form 8-K] [Aptose Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aptose-biosciences-inc-filed-sec-form-8-k-regulation-fd-disclosure-5968727) - 2025-04-01 12:30 UTC [Aptose Common Shares to Delist from Nasdaq as of April 2, 2025](https://www.quantisnow.com/insight/aptose-common-shares-to-delist-from-nasdaq-as-of-april-5968701) - 2025-03-28 14:46 UTC [SEC Form 10-K] [SEC Form 10-K filed by Aptose Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-aptose-biosciences-inc-5964377) - 2025-03-28 12:42 UTC [SEC Form 8-K] [Aptose Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aptose-biosciences-inc-filed-sec-form-8-k-results-of-operations-5964292) - 2025-03-28 12:01 UTC [Aptose Reports Year End 2024 Results and Corporate Highlights](https://www.quantisnow.com/insight/aptose-reports-year-end-2024-results-and-corporate-highlights-5964174) - 2025-03-24 21:02 UTC [SEC Form 8-K] [Aptose Biosciences Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities](https://www.quantisnow.com/insight/aptose-biosciences-inc-filed-sec-form-8-k-unregistered-sales-of-5958056) - 2025-03-21 00:54 UTC [SEC Form 3] [New insider Hanmi Pharmaceutical Co., Ltd. claimed ownership of 508,710 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-hanmi-pharmaceutical-co-ltd-claimed-ownership-of-508710-5955190) - 2025-03-17 11:40 UTC [SEC Form 8-K] [Aptose Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aptose-biosciences-inc-filed-sec-form-8-k-regulation-fd-disclosure-5946354) - 2025-03-17 11:30 UTC [Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance](https://www.quantisnow.com/insight/aptose-biosciences-meets-nasdaq-minimum-bid-price-compliance-5946317) - 2025-02-21 22:12 UTC [SEC Form 8-K] [Aptose Biosciences Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders](https://www.quantisnow.com/insight/aptose-biosciences-inc-filed-sec-form-8-k-material-modification-to-5903471) - 2025-02-20 12:40 UTC [SEC Form 8-K] [Aptose Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aptose-biosciences-inc-filed-sec-form-8-k-regulation-fd-disclosure-5899150) - 2025-02-20 12:32 UTC [Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort](https://www.quantisnow.com/insight/aptose-announces-positive-clinical-safety-review-committee-csrc-approval-to-5899143) - 2025-02-18 21:30 UTC [SEC Form 8-K] [Aptose Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aptose-biosciences-inc-filed-sec-form-8-k-regulation-fd-disclosure-5894355) - 2025-02-18 21:30 UTC [Aptose Announces Reverse Share Split](https://www.quantisnow.com/insight/aptose-announces-reverse-share-split-5894294) - 2025-02-13 22:30 UTC [SEC Form S-1] [SEC Form S-1 filed by Aptose Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-aptose-biosciences-inc-5888367) - 2025-02-13 22:14 UTC [SEC Form 8-K] [Aptose Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities](https://www.quantisnow.com/insight/aptose-biosciences-inc-filed-sec-form-8-k-entry-into-a-5888291) - 2025-02-13 21:42 UTC [SEC Form 8-K] [Aptose Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aptose-biosciences-inc-filed-sec-form-8-k-regulation-fd-disclosure-5888027) - 2025-02-13 21:30 UTC [Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility](https://www.quantisnow.com/insight/aptose-enters-into-25-million-committed-equity-facility-and-establishes-5887859) - 2025-02-12 12:30 UTC [SEC Form 8-K] [Aptose Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aptose-biosciences-inc-filed-sec-form-8-k-regulation-fd-disclosure-5883396) - 2025-02-12 12:00 UTC [Aptose's Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial](https://www.quantisnow.com/insight/aptoses-frontline-triple-drug-therapy-with-tuspetinib-achieves-notable-responses-5883280) - 2025-02-03 21:46 UTC [SEC Form 8-K] [SEC Form 8-K filed by Aptose Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-aptose-biosciences-inc-5867734) - 2025-02-03 21:41 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Aptose Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-aptose-biosciences-inc-5867703) - 2025-01-28 21:31 UTC [SEC Form 8-K] [SEC Form 8-K filed by Aptose Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-aptose-biosciences-inc-5860098) - 2025-01-21 22:21 UTC [SEC Form 8-K] [SEC Form 8-K filed by Aptose Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-aptose-biosciences-inc-5852472) - 2025-01-13 13:01 UTC [SEC Form 8-K] [Aptose Biosciences Inc. filed SEC Form 8-K: Financial Statements and Exhibits](https://www.quantisnow.com/insight/aptose-biosciences-inc-filed-sec-form-8-k-financial-statements-and-5843328) - 2025-01-10 12:00 UTC [SEC Form 8-K] [Aptose Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aptose-biosciences-inc-filed-sec-form-8-k-regulation-fd-disclosure-5840950) - 2025-01-09 21:00 UTC [Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial](https://www.quantisnow.com/insight/aptose-announces-first-aml-patients-dosed-with-tuspetinib-triplet-frontline-5840619) - 2024-12-27 23:59 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Aptose Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-aptose-biosciences-inc-5826359) - 2024-12-27 23:57 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Aptose Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-aptose-biosciences-inc-5826343) - 2024-12-19 21:10 UTC [SEC Form 8-K] [Aptose Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aptose-biosciences-inc-filed-sec-form-8-k-regulation-fd-disclosure-5820491) - 2024-12-19 21:05 UTC [Public Offering] [Aptose Announces Positive Decision by Nasdaq Hearings Panel](https://www.quantisnow.com/insight/aptose-announces-positive-decision-by-nasdaq-hearings-panel-5820420) ## More - Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/APTO - Earnings history: https://www.quantisnow.com/earnings/APTO - Dividend history: https://www.quantisnow.com/dividends/APTO - Insider transactions: https://www.quantisnow.com/insiders/APTO - Options chain: https://www.quantisnow.com/options/APTO - SEC 8-K filings only: https://www.quantisnow.com/company/APTO/8-k - RSS and alerts for APTO: https://www.quantisnow.com/docs/rss-feeds.md